newsfilter
← Latest News
Business Wire·

Spruce Biosciences Joins the Russell 3000® Index

Inclusion Reflects Spruce’s Momentum as the Company Advances Toward a Planned Biologics License Application (BLA) Submission and Potential Commercial Launch of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) for